|
| | 10200HB3080sam001 | - 2 - | LRB102 13965 BMS 41856 a |
|
|
1 | | syndrome, including, but not limited to, the use of |
2 | | intravenous immunoglobulin therapy. |
3 | | No group or individual policy of accident and health |
4 | | insurance or managed care plan shall deny or delay coverage |
5 | | for medically necessary treatment under this Section solely |
6 | | because the insured, enrollee, or beneficiary previously |
7 | | received any treatment, including the same or similar |
8 | | treatment, for pediatric autoimmune neuropsychiatric disorders |
9 | | associated with streptococcal infections or pediatric acute |
10 | | onset neuropsychiatric syndrome, or because the insured, |
11 | | enrollee, or beneficiary has been diagnosed with or receives |
12 | | treatment for an otherwise diagnosed condition. |
13 | | For the purposes of this Section, coverage of pediatric |
14 | | autoimmune neuropsychiatric disorders associated with |
15 | | streptococcal infections and pediatric acute onset |
16 | | neuropsychiatric syndrome shall adhere to the treatment |
17 | | recommendations developed by a medical professional consortium |
18 | | convened for the purposes of researching, identifying, and |
19 | | publishing best practice standards for diagnosis and treatment |
20 | | of such disorders or syndrome that are accessible for medical |
21 | | professionals and are based on evidence of positive patient |
22 | | outcomes. Coverage for any form of medically necessary |
23 | | treatment shall not be limited over a lifetime of an insured, |
24 | | enrollee, or beneficiary or by policy period. Nothing in this |
25 | | Section prevents insurers from requesting treatment notes and |
26 | | anticipated duration of treatment and outcomes. |
|
| | 10200HB3080sam001 | - 3 - | LRB102 13965 BMS 41856 a |
|
|
1 | | For billing and diagnosis purposes, pediatric autoimmune |
2 | | neuropsychiatric disorders associated with streptococcal |
3 | | infections and pediatric acute onset neuropsychiatric syndrome |
4 | | shall be coded as autoimmune encephalitis until the American |
5 | | Medical Association and the Centers for Medicare and Medicaid |
6 | | Services create and assign a specific code for pediatric |
7 | | autoimmune neuropsychiatric disorders associated with |
8 | | streptococcal infections and pediatric acute onset |
9 | | neuropsychiatric syndrome. Thereafter, pediatric autoimmune |
10 | | neuropsychiatric disorders associated with streptococcal |
11 | | infections and pediatric acute onset neuropsychiatric syndrome |
12 | | may be coded as autoimmune encephalitis, pediatric autoimmune |
13 | | neuropsychiatric disorders associated with streptococcal |
14 | | infections, or pediatric acute onset neuropsychiatric |
15 | | syndrome. |
16 | | If, at any time, the Secretary of the United States |
17 | | Department of Health and Human Services, or its successor |
18 | | agency, promulgates rules or regulations to be published in |
19 | | the Federal Register or publishes a comment in the Federal |
20 | | Register or issues an opinion, guidance, or other action that |
21 | | would require the State, pursuant to any provision of the |
22 | | Patient Protection and Affordable Care Act (Public Law |
23 | | 111-148), including, but not limited to, 42 U.S.C. |
24 | | 18031(d)(3)(B) or any successor provision, to defray the cost |
25 | | of any coverage for pediatric autoimmune neuropsychiatric |
26 | | disorders associated with streptococcal infections and |
|
| | 10200HB3080sam001 | - 4 - | LRB102 13965 BMS 41856 a |
|
|
1 | | pediatric acute onset neuropsychiatric syndrome outlined in |
2 | | this Section, then the requirement that an insurer cover |
3 | | pediatric autoimmune neuropsychiatric disorders associated |
4 | | with streptococcal infections and pediatric acute onset |
5 | | neuropsychiatric syndrome is inoperative other than any such |
6 | | coverage authorized under Section 1902 of the Social Security |
7 | | Act, 42 U.S.C. 1396a, and the State shall not assume any |
8 | | obligation for the cost of coverage for pediatric autoimmune |
9 | | neuropsychiatric disorders associated with streptococcal |
10 | | infections and pediatric acute onset neuropsychiatric |
11 | | syndrome.
|
12 | | (Source: P.A. 100-24, eff. 7-18-17; 100-863, eff. 8-14-18; |
13 | | 101-488, eff. 8-23-19.)
|
14 | | Section 99. Effective date. This Act takes effect upon |
15 | | becoming law.".
|